Geode Capital Management
GLUE icon

Geode Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Geode Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.1M Buy
1,864,113
+323,301
+21% +$6.11M ﹤0.01% 1682
2026
Q1 		$25.4M Buy
1,540,812
+335,968
+28% +$6.42M ﹤0.01% 1870
2025
Q4 		$18.9M Buy
1,204,844
+53,278
+5% +$718K ﹤0.01% 2037
2025
Q3 		$8.53M Buy
1,151,566
+27,406
+2% +$145K ﹤0.01% 2503
2025
Q2 		$5.07M Buy
1,124,160
+120,098
+12% +$536K ﹤0.01% 2721
2025
Q1 		$4.66M Sell
1,004,062
-32,603
-3% -$200K ﹤0.01% 2688
2024
Q4 		$7.2M Sell
1,036,665
-8,024
-0.8% -$60.2K ﹤0.01% 2551
2024
Q3 		$5.54M Buy
1,044,689
+197,247
+23% +$996K ﹤0.01% 2706
2024
Q2 		$3.17M Buy
847,442
+111,909
+15% +$571K ﹤0.01% 2958
2024
Q1 		$5.19M Buy
735,533
+47,862
+7% +$284K ﹤0.01% 2684
2023
Q4 		$3.89M Buy
687,671
+40,183
+6% +$158K ﹤0.01% 2831
2023
Q3 		$3.1M Buy
647,488
+34,257
+6% +$221K ﹤0.01% 2883
2023
Q2 		$4.2M Buy
613,231
+30,142
+5% +$195K ﹤0.01% 2782
2023
Q1 		$4.54M Buy
583,089
+19,742
+4% +$137K ﹤0.01% 2676
2022
Q4 		$4.29M Buy
563,347
+33,235
+6% +$277K ﹤0.01% 2744
2022
Q3 		$4.33M Buy
530,112
+152,109
+40% +$1.4M ﹤0.01% 2751
2022
Q2 		$3.65M Buy
378,003
+20,328
+6% +$204K ﹤0.01% 2868
2022
Q1 		$5.01M Buy
357,675
+141,674
+66% +$1.97M ﹤0.01% 2799
2021
Q4 		$4.41M Buy
216,001
+20,218
+10% +$423K ﹤0.01% 2962
2021
Q3 		$4.36M Buy
+195,783
New +$5.61M ﹤0.01% 2989

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management's GLUE Position: Q2 2026 in Review

Geode Capital Management increased its Monte Rosa Therapeutics (GLUE) stake by 21% in Q2 2026, buying an estimated $6.11M and bringing the position to 1,864,113 shares worth $45.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1682.

Geode Capital Management first reported a position in GLUE in Q3 2021 and has held it in 20 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Geode Capital Management held 1,864,113 shares of Monte Rosa Therapeutics worth $45.1M as of Q2 2026.
  • Geode Capital Management bought 323,301 Monte Rosa Therapeutics shares in Q2 2026, an estimated $6.11M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1682 holding.
  • Geode Capital Management first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.